Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Moderna and Pfizer have released data suggesting that their vaccines are well tolerated in adolescents and highly effective in preventing COVID-19. Canada, the US and the EU have already authorised the Pfizer vaccine in children as young as 12. And the UK has just approved the use of the Pfizer vaccine in children aged 12 to 15. But there may a case for holding out on an immediate rollout, for several reasons.
Whether a vaccine is beneficial for someone depends on three things: how likely they are to become seriously ill from the infection, how effective the vaccine is, and the risks of vaccination.
Children have less severe COVID-19 than adults. A recent study across seven countries suggests that there were less than two in a million COVID deaths in children. Even if the vaccine is highly effective in children, it can only eliminate an already tiny risk. Of course, there are other problems, such as long COVID, but we don’t know yet how common this is in children.
We also have to weigh the benefits against vaccine side-effects. So far, trials are reassuring, but those studies only gave the vaccine to about 3,000 young people (aged 12 to 17). They are not large enough to identify rare events. For example, the blood clots associated with the AstraZeneca vaccine were not seen in the much larger initial adult trials.
